Immune reconstitution following hematopoietic progenitor cell transplantation: Challenges for the future

Bone Marrow Transplantation

Volumn 35, Issue , 2005, Pages S53-S57

  Fry, T J ^a   Mackall, C L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

GVHD; Homeostatic peripheral expansion; IL 7; Keratinocyte growth factor; Thymopoiesis

Indexed keywords

ANTINEOPLASTIC AGENT; FLT3 LIGAND; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 7; KERATINOCYTE GROWTH FACTOR; SEX HORMONE ANTAGONIST; TUMOR VACCINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SAFETY; T LYMPHOCYTE; THYMUS DISEASE; THYMUS FUNCTION;

ANIMALS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM; RECOVERY OF FUNCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 18144394761     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704848     Document Type: Article

References (34)

1. Ochs L, Shu XO, Miller J et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86: 3979-3986.
2. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 1997; 26: 1-15.
3. Storek J, Espino G, Dawson MA et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96: 3290-3293.
4. Chen CS, Boeckh M, Seidel K et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 515-522.
5. Storek J. B-cell immunity after allogeneic hematopoietic cell transplantation. Cytotherapy 2002; 4: 423-424.
6. Storek J, Viganego F, Dawson MA et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 2003; 101: 3319-3324.
7. Miller RA, Stutman O. T cell repopulation from functionally restricted splenic progenitors: 10 000-fold expansion documented by using limiting dilution analyses. J Immunol 1984; 133: 2925-2932.
8. Stutman O. Postthymic T-cell development. Immunol Rev 1986; 91: 159-194.
9. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997; 157: 61-72.
10. Fry TJ, Christensen BL, Komschlies KL et al. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 2001; 97: 1525-1533.
11. Hakim FT, Cepeda R, Kaimei S et al. Constraints on CD4 recovery post chemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997; 90: 3789-3798.
12. Mackall CL, Bare CV, Titus JA et al. Thymic-independent T cell regeneration occurs via antigen driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996; 156: 4609-4616.
13. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 1999; 11: 183-190.
14. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402: 255-262.
15. Weinberg K, Blazar BR, Wagner JE et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001; 97: 1458-1466.
16. Douek DC, Vescio RA, Betts MR et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355: 1875-1881.
17. Roux E, Helg C, Fumont-Girard F et al. Analysis of T cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984-3992.
18. Zinkernagel RM, Althage A, Callahan G, Welsh RM. On the immunocompetence of H-2 incompatible irradiation bone marrow chimeras. J Immunol 1980; 124: 2356-2365.
19. Ghayur T, Seemayer TA, Xenocostas A, Lapp WS. Complete sequential regeneration of graft-vs-host induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs-host disease. Am J Pathol 1988; 133: 39-46.
20. Fukushi N, Arase H, Wang B et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. PNAS 1990; 87: 6301-6305.
21. Brochu S, Rioux-Masse B, Roy J et al. Massive activationinduced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 1999; 94: 390-400.
22. Porter DL, Collins RH, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
23. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477-1486.
24. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998; 29: 301-313.
25. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
26. Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
27. Min D, Taylor PA, Panoskaltsis-Mortari A et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002; 99: 4592-4600.
28. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20: 394-397.
29. Fry TJ, Moniuszko M, Creekmore S et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101: 2294-2299.
30. Sinha ML, Fry TJ, Fowler DH et al. Interleukin 7 worsens graft-versus-host disease. Blood 2002; 100: 2642-2649.
31. Fry TJ, Sinha M, Milliron M et al. Flt 3 ligand enhances thymic-dependent and thymic-independent immune reconstitution. Blood 2004; 104: 2794-2800.
32. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
33. Napolitano LA, Lo JC, Gotway MB et al. Increased thymic mass and circulating naive CD4T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002; 16: 1103-1111.
34. Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development. Immunol Res 2001; 23: 281-288.